AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the (NKF SCM25), which will take place in Boston, MA from April 10-13, 2025.

Akebia-supported posters will be displayed at NKF SCM25 during Exhibit Hall hours.

  • Cardiovascular Risk in Patients With DD-CKD Randomized to Vadadustat vs Darbepoetin Alfa With or Without Cardiovascular Disease:



  • Vadadustat for Treatment of Anemia in Older vs Younger Patients With Dialysis-Dependent-CKD:

On Thursday, April 10, 2025 at 4:00 pm during at NKF SCM25, Dr. Wolfgang Winkelmayer will present a poster titled “Vadadustat for Treatment of Anemia in Older vs Younger Patients With Dialysis-Dependent-CKD.”

NKF SCM25 attendees can also visit Akebia at Booth #1121 in the Exhibit Hall.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at , which does not form a part of this release.

Akebia Therapeutics Contact

Mercedes Carrasco



EN
25/03/2025

Underlying

AKBAAkebia Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Akebia Therapeutics Inc.

 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rul...

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 13 newly-hired employees options to purchase an aggregate of 679,900 shares of Akebia’s common stock on March 31, 2026. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise...

16m 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, ...

Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors CAMBRIDGE, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of biopharmaceutical leader Philip J. Vickers to its Board of Directors, effective April 1, 2026. Dr. Vickers is the President and Chief Executive Officer and a member of the Board of Directors of Solu Therapeutics, a venture-backed biotechnology company focused on creating first-in-clas...

April 1, 2026 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics to Present at the Leerink Partners 2026 Global Hea...

Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in a Fireside Chat at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9 at 8:00 AM ET. A webcast of the presentation can be accessed through the “Investors” section o...

March 3, 2026 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rul...

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted five newly-hired employees options to purchase an aggregate of 46,200 shares of Akebia’s common stock on February 27, 2026. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exer...

March 2, 2026 1 EN
 PRESS RELEASE
Free
AKBA Akebia Therapeu...

Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financia...

Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights Q4 2025 net product revenues of $54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 full-year net product revenues Expect significant Vafseo® (vadadustat) revenue growth in 2026 through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates Pipeline advancement continues with enrollment underway for praliciguat Phase 2 clinical trial in focal segmental glomerulosclero...

February 26, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch